Bert Schepens, PhD

staff scientist
VIB/Ghent University, Belgium

Disclosure(s): Exevir: Bert Schepens is Inventor on patents that describe the nanobodies that are mentioned in the abstract and presentation

Poster(s):

• (P-2023) A ‘Variant-Proof’ Cocktail Of Two Heavy Chain-Only Antibodies Targets 3 Epitopes In The Spike Protein S1 And S2 Subunits And Broadly Neutralizes SARS-Cov-2 With Exceptional Potency
  Saturday, October 19, 2024

  12:15 PM – 1:30 PM US PT